Optimizing the CAR to express the appropriate chemokine receptor to the tumor could improve trafficking and anti-tumor effect, as shown in a study of GD2-CAR T cells expressing CCR2b in CCL2-secreting tumors [195]. The gene discussed is CCL2; the disease is neoplasm.